PRODUCT LITERATURE

Effect of Amlodipine + Candesartan on Cardiovascular Events in Hypertensive Patients With Coronary Artery Disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study)

---

Combination therapy with calcium channel blockers and angiotensin II receptor blockers
is recommended as one of the effective therapies for hypertension. However, it remains
unclear whether this combination reduces major adverse cardiovascular events (MACEs) in
patients with hypertension with coronary artery disease (CAD). The purpose of the present
study was to examine the effects of amlodipine plus candesartan on MACEs in patients
with hypertension with CAD. The study population was drawn from The Heart Institute
of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease
(HIJ-CREATE), which was a multicenter, prospective, randomized controlled trial including 2,049 patients with hypertension with angiographically documented CAD. Subgroup
analysis was performed in patients treated with amlodipine at baseline (n 388). The
median follow-up period was 4.3 years. Treatment using amlodipine plus candesartan
reduced the risk for MACEs by 39% (p 0.015) compared to that using amlodipine
without angiotensin II receptor blockers. Among the individual events constituting
MACEs, the incidence of unstable angina pectoris requiring hospitalization was significantly lower, by 52% (p 0.007). In conclusion, amlodipine plus candesartan demonstrated a more favorable effect on reducing cardiovascular events in patients with hypertension with CAD compared to amlodipine-based therapy without candesartan

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Hypertension
Canderin Duo
Amlodipine + Candesartan

Specific Detail Info

The American Journal of Cardiology, 106(6), 819–824

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment